Literature DB >> 25288640

Genetic dissection of the vav2-rac1 signaling axis in vascular smooth muscle cells.

Salvatore Fabbiano1, Mauricio Menacho-Márquez1, María A Sevilla2, Julián Albarrán-Juárez3, Yi Zheng4, Stefan Offermanns3, María J Montero2, Xosé R Bustelo5.   

Abstract

Vascular smooth muscle cells (vSMCs) are key in the regulation of blood pressure and the engagement of vascular pathologies, such as hypertension, arterial remodeling, and neointima formation. The role of the Rac1 GTPase in these cells remains poorly characterized. To clarify this issue, we have utilized genetically engineered mice to manipulate the signaling output of Rac1 in these cells at will using inducible, Cre-loxP-mediated DNA recombination techniques. Here, we show that the expression of an active version of the Rac1 activator Vav2 exclusively in vSMCs leads to hypotension as well as the elimination of the hypertension induced by the systemic loss of wild-type Vav2. Conversely, the specific depletion of Rac1 in vSMCs causes defective nitric oxide vasodilation responses and hypertension. Rac1, but not Vav2, also is important for neointima formation but not for hypertension-driven vascular remodeling. These animals also have allowed us to dismiss etiological connections between hypertension and metabolic disease and, most importantly, identify pathophysiological programs that cooperate in the development and consolidation of hypertensive states caused by local vascular tone dysfunctions. Finally, our results suggest that the therapeutic inhibition of Rac1 will be associated with extensive cardiovascular system-related side effects and identify pharmacological avenues to circumvent them.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25288640      PMCID: PMC4248731          DOI: 10.1128/MCB.01066-14

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  47 in total

1.  Phosphorylation of caldesmon by p21-activated kinase. Implications for the Ca(2+) sensitivity of smooth muscle contraction.

Authors:  D B Foster; L H Shen; J Kelly; P Thibault; J E Van Eyk; A S Mak
Journal:  J Biol Chem       Date:  2000-01-21       Impact factor: 5.157

Review 2.  Regulatory and signaling properties of the Vav family.

Authors:  X R Bustelo
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

Review 3.  VAV proteins as signal integrators for multi-subunit immune-recognition receptors.

Authors:  Martin Turner; Daniel D Billadeau
Journal:  Nat Rev Immunol       Date:  2002-07       Impact factor: 53.106

4.  Structural determinants for the biological activity of Vav proteins.

Authors:  José L Zugaza; Miguel A López-Lago; María J Caloca; Mercedes Dosil; Nieves Movilla; Xosé R Bustelo
Journal:  J Biol Chem       Date:  2002-09-12       Impact factor: 5.157

5.  The C-terminal SH3 domain contributes to the intramolecular inhibition of Vav family proteins.

Authors:  María Barreira; Salvatore Fabbiano; José R Couceiro; Eva Torreira; Jorge L Martínez-Torrecuadrada; Guillermo Montoya; Oscar Llorca; Xosé R Bustelo
Journal:  Sci Signal       Date:  2014-04-15       Impact factor: 8.192

6.  Signal transduction through Vav-2 participates in humoral immune responses and B cell maturation.

Authors:  G M Doody; S E Bell; E Vigorito; E Clayton; S McAdam; R Tooze; C Fernandez; I J Lee; M Turner
Journal:  Nat Immunol       Date:  2001-06       Impact factor: 25.606

7.  Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle.

Authors:  V Sauzeau; H Le Jeune; C Cario-Toumaniantz; A Smolenski; S M Lohmann; J Bertoglio; P Chardin; P Pacaud; G Loirand
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

Review 8.  Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?

Authors:  Dominico Vigil; Jacqueline Cherfils; Kent L Rossman; Channing J Der
Journal:  Nat Rev Cancer       Date:  2010-11-24       Impact factor: 60.716

Review 9.  Essential hypertension.

Authors:  Jan A Staessen; Jiguang Wang; Giuseppe Bianchi; Willem H Birkenhäger
Journal:  Lancet       Date:  2003-05-10       Impact factor: 79.321

Review 10.  Nitric oxide-releasing drugs.

Authors:  Claudio Napoli; Louis J Ignarro
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002-01-10       Impact factor: 13.820

View more
  13 in total

1.  p115 RhoGEF activates the Rac1 GTPase signaling cascade in MCP1 chemokine-induced vascular smooth muscle cell migration and proliferation.

Authors:  Nikhlesh K Singh; Jagadeesh Janjanam; Gadiparthi N Rao
Journal:  J Biol Chem       Date:  2017-06-27       Impact factor: 5.157

2.  Sustained Activation of Rho GTPases Promotes a Synthetic Pulmonary Artery Smooth Muscle Cell Phenotype in Neprilysin Null Mice.

Authors:  Vijaya Karoor; Mehdi A Fini; Zoe Loomis; Timothy Sullivan; Louis B Hersh; Evgenia Gerasimovskaya; David Irwin; Edward C Dempsey
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11-30       Impact factor: 8.311

3.  MST3 promotes proliferation and tumorigenicity through the VAV2/Rac1 signal axis in breast cancer.

Authors:  Chien-Yu Cho; Kuo-Ting Lee; Wei-Ching Chen; Chih-Yang Wang; Yung-Sheng Chang; Hau-Lun Huang; Hui-Ping Hsu; Meng-Chi Yen; Ming-Zong Lai; Ming-Derg Lai
Journal:  Oncotarget       Date:  2016-03-22

4.  Prelamin A Accumulation Attenuates Rac1 Activity and Increases the Intrinsic Migrational Persistence of Aged Vascular Smooth Muscle Cells.

Authors:  Lauren J Porter; Mark R Holt; Daniel Soong; Catherine M Shanahan; Derek T Warren
Journal:  Cells       Date:  2016-11-15       Impact factor: 6.600

5.  Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models.

Authors:  María Rico; María Baglioni; Maryna Bondarenko; Nahuel Cesatti Laluce; Viviana Rozados; Nicolas André; Manon Carré; O Graciela Scharovsky; Mauricio Menacho Márquez
Journal:  Oncotarget       Date:  2017-01-10

6.  Next-generation sequencing identifies novel genes with rare variants in total anomalous pulmonary venous connection.

Authors:  Xin Shi; Tao Huang; Jing Wang; Yulai Liang; Chang Gu; Yuejuan Xu; Jing Sun; Yanan Lu; Kun Sun; Sun Chen; Yu Yu
Journal:  EBioMedicine       Date:  2018-11-16       Impact factor: 8.143

7.  Drug Vulnerabilities and Disease Prognosis Linked to the Stem Cell-Like Gene Expression Program Triggered by the RHO GTPase Activator VAV2 in Hyperplastic Keratinocytes and Head and Neck Cancer.

Authors:  Luis Francisco Lorenzo-Martín; Mauricio Menacho-Márquez; Xosé R Bustelo
Journal:  Cancers (Basel)       Date:  2020-09-03       Impact factor: 6.575

8.  Next Generation Sequencing Identify Rare Copy Number Variants in Non-syndromic Patent Ductus Arteriosus.

Authors:  Bo Chen; Aiping Hou; Lin Zhao; Ying Liu; Xin Shi; Bowen Du; Yu Yu; Pengjun Zhao; Ying Gao
Journal:  Front Genet       Date:  2020-11-12       Impact factor: 4.599

9.  Vav2 pharmaco-mimetic mice reveal the therapeutic value and caveats of the catalytic inactivation of a Rho exchange factor.

Authors:  L Francisco Lorenzo-Martín; Sonia Rodríguez-Fdez; Salvatore Fabbiano; Antonio Abad; María C García-Macías; Mercedes Dosil; Myriam Cuadrado; Javier Robles-Valero; Xosé R Bustelo
Journal:  Oncogene       Date:  2020-06-11       Impact factor: 9.867

Review 10.  Vav family exchange factors: an integrated regulatory and functional view.

Authors:  Xosé R Bustelo
Journal:  Small GTPases       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.